DAY 1 – September 24
Keynote: Oliver Kappe – University of Graz
15 Years of Academia-Industry Collaborations in Flow Chemistry
This lecture will summarize selected case studies resulting from over 100 joint projects/publications of the CCFLOW team in Graz with pharma companies, CDMOs, etc. in the general field of flow chemistry and continuous manufacturing since 2010. Emphasis will be given to the different drivers moving from batch to flow and the lessons learned in these 15 years.
–
Andrew Rutter – rutterdesign
What is the impact after 25 years of flow chemistry and continuous manufacture in Pharma API manufacture?
Having been a pioneer in this field, it feels a good time to look back and assess the state of the art. I will explore what has changed; what application are now routine, and what are not. I will also explore the change in the ecosystem to apply continuous processing, in regulation, maturity of vendors, and CMOs. Finally, I will share my views on what value drivers for advanced manufacturing are being met and missed.
–
Franz Strauß – Microinnova Engineering
Utilization of liquified gases using continuous flow technology
Liquified gases such as ammonia, methylamine, sulfur tetrafluoride, and ethylene oxide represent a class of highly reactive and industrially important reagents, enabling key transformations such as amination, fluorination, and epoxidation. Despite their synthetic potential, the use of these reagents in research and development environments has historically been limited due to challenges associated with their volatility, toxicity, and complex handling requirements. In large scale batch processes, the formation of a gas–liquid interface can lead to poor mass transfer, inconsistent reaction performance, and elevated safety risks.
In this work, we demonstrate how continuous flow technology, combined with elevated system pressure, enables the safe, reproducible, and scalable use of liquified gases under fully liquid-phase conditions for both research and production scale. Maintaining these reagents in the liquid state throughout the reaction stream eliminates the gas–liquid boundary, significantly enhancing heat and mass transfer, reaction uniformity, and control over stoichiometry. The pressurized flow setup minimizes operator exposure and reactor size while enabling precise dosing and rapid parameter screening together with maximum production efficiency.
Case studies include the continuous amination of alkyl halides using liquified ammonia, reductive amination using methylamine, fluorination strategies involving sulfur tetrafluoride, and ring-opening reactions with ethylene oxide. In each case, continuous flow operation not only improves safety and reproducibility but also opens opportunities for process intensification and seamless scale-up.
Our findings highlight the strategic advantages of integrating liquified gases into modern R&D pipelines and production scale strategies through continuous flow. This methodology provides a robust platform for expanding the accessible chemical space while aligning with principles of green chemistry, safety, and process efficiency. We believe that this approach will serve as a blueprint for the broader adoption of challenging gas-phase reagents in academic and industrial research settings.
–
Ricardo Labes – Syngenta
From Flask to Field: Flow Chemistry at Syngenta and its Path to Resource Optimisation
Syngenta is one of the world’s leading agricultural technology and science companies employing 49,000 people in over 100 countries. Continuous flow chemistry plays a vital role in its research and development, from lead generation in discovery, to process research and development. The talk will include examples of flow chemistry being used to improve speed, safety, scale-up and process understanding, with focusing on recent developments towards miniaturisation. The platform, developed in partnership with Vapourtec allows for reactions to be run in volumes as low as 100 µL, decoupling dispersion, while allowing longer reaction times and maintaining steady state. This allows minimal material consumption for optimisation, and subsequential scale-up using the conditions found.
–
Michael Nonnenmacher- Evonik Operations
Self-Driving Labs at Evonik Health Care
Evonik has a long history and strong background in continuous processing, with more than two-thirds of the company’s product volume manufactured in a continuous fashion. At Evonik Health Care, this technology is leveraged to add value to pharmaceutical products, both in the drug substance and drug product spaces. At Evonik`s Competence Center for Simulation and Additive Manufacturing (SAM 3D), innovative methods for designing sustainable, next-generation reactors are being implemented as part of the publicly funded project 3D-PROCESS* with the aim to reduce energy consumption and further minimize the environmental footprint of the processes.
In this project, Evonik has developed and integrated AI-supported process and reactor development tools, rolling out the technology to its API process development workflow. The presentation will showcase relevant examples and discuss both challenges and achievements.
References and notes
*3D PROCESS- Disruptive Digital Design – funded by German Federal Ministry for Economic Affairs and Energy
–
Hendrik Held – Ehrfeld Mikrotechnik
Thomas Kretzschmar – Hitec Zang
Flowing Together: Integrating Automation and Scale-Up in Holistic Process Design
This oral tandem presentation of Ehrfeld Mikrotechnik and HiTec Zang introduces a holistic approach to process development, where flow chemistry, automation, and scale-up are integrated from the very first lab trials. By designing with production in mind from the start, development cycles become faster, more efficient, and more sustainable.
HiTec Zang’s modular automation systems allow researchers to quickly adapt lab setups and test new process steps with minimal effort. In parallel, Ehrfeld Mikrotechnik’s MMRS platform offers a flexible, modular, and scalable reactor architecture that supports seamless transitions from lab to production scale.
The synergy of modular automation and modular reactor design enables highly efficient experimentation. Improved reproducibility and fewer outliers reduce the need for repeat trials. When combined with data-driven methods such as Bayesian optimization, the total number of experiments can be significantly lowered – saving time, materials, and energy.
Digital twins offer new potential for in-silico process optimization. Their development relies on high-quality experimental data, which is generated through reliable process analysis tools (PAT) and automated data evaluation, storage, and interpretation. These real-world datasets form the foundation for training and validating virtual models that simulate process behavior under varying conditions.
Case studies will highlight how this integrated approach enables faster, greener, and more reliable innovation – flowing together from lab to production.
–
Chinmay Joglekar – AstraZeneca
Micromixing characterisation of reactors to drive efficient scale-up of continuous processes
Continuous manufacturing is expected to play a critical role in AstraZeneca’s commitment to sustainable manufacturing. AstraZeneca has adopted a modular approach to continuous manufacturing where each module consists of a key component within a continuous equipment train which is fully reconfigurable based on process requirements.
Reactors are the heart of a continuous equipment train. Reactor characteristics play a key role in the decision to choose a particular type of reactor for scale-up of a process from lab to pilot / commercial scale.
This includes characteristics such as mixing performance, heat transfer characteristics and Residence Time Distribution (RTD) response of the reactors.
In batch processes, well developed empirical correlations exist which can give an indication of suitability of equipment at scale for a particular process. However, in continuous manufacturing, such correlations do not exist as the technology is still in its nascent stage and reactor designs are highly bespoke.
As the end users, it is therefore essential to characterise both lab and plant scale equipment to build a database of reactor characteristics. Once different reactor types have been characterised, scale-up and tech transfer decisions would become easier by narrowing down the choice of reactors based on requirements for a process e.g. a certain minimum micromixing time or minimum heat transfer requirement to avoid impurity formation.
This presentation would give an overview of our approach to implementing micromixing characterisation of continuous flow reactors using the widely reported
Villermaux-Dushman protocol on the pilot plant. Use of PAT, online monitoring and data visualisation techniques would also be highlighted.
–
Lara Nolan – Almac Sciences
A CDMO journey to scaling continuous processes
Scaling up flow processes in the fine chemical and pharmaceutical industries is underpinned by the integration of chemical engineering and process chemistry.
Flow processing is paramount for achieving efficiency, productivity, and sustainability within chemical manufacture. At Almac, a hub of chemical and engineering innovation, the implementation of scalable flow processes has revolutionized the way chemical processes are performed, ensuring that the transition from laboratory scale to industrial scale is seamless and effective.
The importance of robust scalability of flow processes lies in its ability to foster innovation in supply chains, reduce costs, and minimize environmental impacts for chemical manufacture. By focusing on scalability, Almac has been able to optimize its chemical processes, ensuring that they are both economically viable and environmentally responsible. This presentation showcases examples in high pressure hydrogenation and low temperature organometallics for formylation projects scaled to 100’s kilograms.
–
Arne Vancleef – InnoSyn
Aerobic Alcohol Oxidations from Lab-Scale to Industrial Implementation: Batch or Flow?
Aerobic oxidations of alcohols catalyzed by nitroxyl radicals such as TEMPO and keto-ABNO are a selective, fast, cheap and eco-friendly way of synthesizing carbonyl compounds. However, aerobic oxidations always create engineering challenges regarding process safety and heat- and mass transfer that determine the industrial viability of these reactions. Continuous flow reactors are perfectly suited to handle these challenges, especially when working in a single-phase flow.
Yet, traditional multipurpose batch reactors can also overcome these challenges and, depending on the substrate, have their advantages. Both approaches are investigated on productivity, process safety and scalability.
Case studies were performed on a primary and secondary alcohols and both can be oxidized in a scalable and safe manner in batch and flow.
However, there are clear advantages and disadvantages to both approaches.
The primary alcohol is oxidized using TEMPO and the productivity heavily benefitted from the flow process as it enabled the intrinsic catalyst kinetics to operate without constraints.
This led to a 200 fold increase in productivity; obtaining a yield of 96% in less than 5 minutes at concentrations of 25 wt% of substrate under safe conditions that are straightforward to scale-up.
On the other hand the secondary alcohols using ketoABNO suffered from faster catalyst deactivation in flow due to the higher catalyst oxidation. Consequently, the batch process can operate at lower ketoABNO concentrations, as low as 0.3 mol%.
In conclusion, both batch and flow are suitable for aerobic oxidations.
Flow is excellent for all important industrial aspects, especially towards productivity, nevertheless, batch is also a viable approach and requires less catalyst when working with secondary alcohols.
–
Thomas Biellmann – Qfluidics
Magnetically Confined Liquid-Walled Flow Reactors for Solid-Tolerant Continuous Processes
The widespread adoption of continuous flow chemistry is still limited by the incompatibility of conventional reactors with solid-laden streams. Clogging, abrasion, and unplanned downtimes remain major obstacles for processes involving precipitation or heterogeneous catalysts, despite the well-documented benefits of flow chemistry over batch processing. Notably, nearly two-thirds of potentially transferable batch processes are currently excluded from flow implementation due to solid-handling issues.
We introduce a new class of liquid-walled flow reactors, where diamagnetic reaction media are magnetically confined inside ferrofluid “jackets” maintained by a quadrupolar magnetic field.
These self-healing, clog-resistant liquid tubes adapt to suspended solids without fouling or abrasion. Their soft, deformable walls enable plug flow behavior, up to 10× enhanced micromixing and ultra-low fluid drag.
To illustrate their performance, we report the continuous formylation of aryl bromides, a representative reaction prone to in-line precipitation and fouling in traditional microreactors. Using our platform, the reaction proceeds with excellent yield and selectivity under uninterrupted operation, even under solid-loading conditions that would otherwise compromise performance.
This work demonstrates a scalable, passive, and robust reactor platform for solid-tolerant flow chemistry, paving the way for continuous heterogeneous catalysis, crystallization, and other slurry-based transformations—without the need for segmenting techniques, sonication, or oscillatory flow designs.
The liquid-walled design represents a significant advancement in expanding the usable chemical space in flow and meeting the practical needs of industrial chemistries.
–
Andrea Adamo – Zaiput Flow Technologies
A new stacked, continuous, scalable, high performance crystallizer
Process developers in the pharmaceutical industry lack a readily deployable, standardized, off-the-shelf continuous crystallization setup, abiding the low material requirements of early product development.1 The mixed-suspension-mixed-product-removal crystallizer (MSMPRC) offers the highest flexibility in terms of residence time and agitation intensity, making it the most commonly used continuous crystallization platform.
By operating a series of MSMPRCs, quasi plug flow behavior can be attained by narrowing the residence time distribution (RTD) enabling superior control over the product’s critical quality attributes compared to a single stage. However, slurry transfer in continuous operation poses significant hurdles, particularly at the lab-scale, where the reduced size of the equipment’s transfer lines increases the risks of classification and clogging.
In this work we present a novel stacked continuous crystallizer, hosting 11 tanks in series (~80 mL total volume) with a novel diaphragm driven slurry transfer which eliminates the need for transfer lines.
RTD measurements reveal nearly ideal mixing and transport behavior throughout the cascade.
Solids’ handling is assessed with different crystal size distributions (CSDs) of a model compound, and high speed imaging. The results are evaluated by comparison with the tanks in series model. After presenting the technology and the characterization of its key performance parameters, we discussed examples of crystallization and scale up.
–
Niels Klement – Flowid
Scaling up controlled precipitations in flow
In this presentation we focus on the production of solids in flow, on the industrial scale. Solids are common products of the chemical industry. Though, most chemistry is done in the liquid state.
As such precipitations are important in many processes. Precipitations are readily done in batch reactors. However, they can produce solids that may be substantially polydisperse, tough to separate, or all around challenging to work with. These issues may become more severe when precipitations are done on a larger scale, for example when tonnes of precipitate are to be separated from a vat, or if grown crystals are simply too large for downstream processing.
Performing precipitations in flow may offer solutions. Flow reactors are by definition smaller, resulting in reduced volumes for precipitate to grow in, and reduced volumes that need to be separated at all times. Though, precipitations in flow come with their own challenges. Flow in itself does not affect the polydispersity of produced solids. Furthermore, continuous production of solids can result in clogging of pipes, reducing overall reliability of the process.
Here, we show that strong agitation in a continuous precipitation process prevents clogging and substantially reduces polydispersity of formed solids. We use dynamic reactor technology with high heat transfer and Reynolds numbers to perform precipitations in a very controlled manner.
Scale up is possible by tuning flow rates, increasing reactor sizes, or both. Additionally, we show that the in-flow produced solids are easily separated in-line by filtration. We show data and results on polydispersity, particle size and throughput from a real-world implementation. We anticipate that this way of performing precipitations in a continuous manner, as well as scaling them up, will be of broad applicability in the chemical industry.
DAY 2 – September 25
Keynote: Gareth Alford – AstraZeneca
Continuous API as a Platform Technology for Agile, Sustainable Manufacturing of API
Presentation will look to cover the changing environment in pharmaceutical manufacturing and how the use of modular processing platforms for continuous manufacturing can be used to provide the agility needed to manage the ever increasing complexity of API development and manufacture. The intent will be to share the current platform approaches that are being used within pharma and to look to call out where further collaboration is required in ensuring the wider supply chain is suitably ready to support the challenges we face with both internal and external factors such as sustainable manufacture and geopolitical forces.
Focus will then look at the areas where further industry collaboration is needed in more detail around both the technical areas (Modular plant design and operation using digitalisation) as well as developing wider standards and approaches with agencies and key technology supplier groups. Finally there will be a call for the industry to look at how we drive these disruptive changes in a manner that supports the patients while delivering against an aggressive timeline.
–
Lana Borukhova – Sanofi
Hybrid Manufacturing: Reshaping the Pharmaceutical Landscape with Continuous Flow and Automated Batch Integration
The pharmaceutical industry is navigating an era of heightened regulatory scrutiny, increasing development costs, and shifting market demands that prioritize speed, efficiency, and sustainability. Traditional batch manufacturing, while historically dominant, presents inefficiencies in
scalability and operational robustness, particularly for complex small molecule APIs.
Meanwhile, continuous manufacturing has emerged as a transformative approach, offering enhanced control over process conditions and improved efficiency. However, its universal applicability remains limited. The next evolution of pharmaceutical manufacturing lies in the seamless integration of continuous flow reactors with small-volume, automated batch systems.
This hybrid manufacturing architecture enables process intensification at multiple levels—combining the precision and efficiency of flow with the multi-purposeless of batch operations. Current presentation shares the commercial readiness level and the remaining challenges within the implementation of this approach.
–
Simon Coleman – DEC Group / Alconbury Weston Ltd
The ‘new world’ continuous. Designing a continuous processing plant using DEC’s advanced configurable process plant (ACPP)
DEC Group is a leading supplier of true end-to-end solutions, continuous and hybrid systems. Alconbury Weston Ltd (AWL), part of the DEC Group, supplies continuous reaction, extraction, crystallization and filtration/drying equipment.
AWL will demonstrate how Modular Type Packages (MTP) can be used to allow for flexible and configurable connections of unit operation modules, and how this can deliver a multi-modular advanced configurable process plant (ACPP) for both development and production.
A new case study for a reconfigurable API processing plant processing multiple API products will be presented. Data from the chemistry trials for this project will be shown, including enzymatic reaction trials, filtration and washing trials, as well as a Gap Analysis for the design of a multi-API production system.
The talk will show how to overcome continuous processing barriers by learning strategies to reduce complexity and compliance challenges. An example of a hybrid processing solution will be presented, demonstrating the benefits of combining batch, semi-continuous, and continuous operations.
–
Mike Gordon – ReelReactor
ReelReactor™: A Peristaltic Micro-Batch Approach to Flow Chemistry Reactions
ReelReactor™ was created to solve a persistent challenge in continuous flow systems: achieving uniform residence times and reliable mixing under laminar, low-pressure conditions. In traditional plug flow reactors, the no-slip boundary condition creates a parabolic velocity profile, fastest at the center, zero at the walls, leading to axial dispersion that broadens residence times and undermines reaction control.
To address this, ReelReactor™ uses a peristaltic mechanism to divide flow into discrete, mechanically isolated micro-batches. Each travels through the system with a consistent residence time and formulation profile. Continuous, gentle mixing arises from the relative motion between fluid and tubing, eliminating the need for static mixers or internal agitation. The system employs single-use, functionally closed consumables that support sterile operation and rapid changeover, key requirements in regulated environments.
Originally developed for gene editing and viral vector production, ReelReactor™ enables batch-sensitive biological workflows to move to continuous manufacturing. These applications often involve short, formulation-critical reactions that are difficult to scale with conventional systems. A continuous approach that preserves timing and product uniformity offers a path to greater scalability, lower cost, and higher quality.
Alternative segmentation methods, such as gas slugs or carrier fluids, face major limitations. Carrier fluids are rarely used in biologics due to validation burdens and the need for downstream filtration, which is often incompatible with sensitive products. Gas segmentation, while effective at microscale, becomes unstable at larger volumes due to bubble coalescence and scale-dependent behavior.
In a feasibility study with Thermo Fisher Scientific, ReelReactor™ was used in a model gene delivery workflow to prepare DNA–lipid complexes for cell transfection. Plasmid DNA encoding green fluorescent protein (GFP) was combined with Lipofectamine™ 2000 and incubated for ten minutes before application to human cells (HEK293). After 24 hours, cell analysis confirmed successful gene transfer. ReelReactor™ delivered time-sensitive complexes with performance comparable to batch, while running continuously.
–
Luke Rogers – On Demand Pharmaceuticals
Set it and forget it? The myths and realities of push-button chemistry
The concept of “push-button chemistry” evokes a future of fully autonomous pharmaceutical manufacturing. But in practice, particularly for complex, multi-step processes, automation remains deeply dependent on human insight and iterative development. This talk explores that reality through the case study of midazolam, a sterile-injectable sedative that experiences routine critical shortages.
Historically, the final step in midazolam synthesis, a thermal decarboxylation of a tricyclic acid (TCA) intermediate, has been troubled by the formation of isomidazolam, a structurally similar isomer that is difficult to purge and must be controlled below 0.1% LCAP. Conventional processes often yield 1–15% isomidazolam, increasing purification burden and limiting scalability.
We developed an acid-mediated hot-melt decarboxylation strategy that consistently achieves >95% instantaneous yield and suppresses isomidazolam formation to <0.3% in crude product. To implement this step continuously, we designed a gravity-fed melt reactor composed of heated, stacked aluminum plates. Solid TCA is fed to the top, melted, and conveyed downward through a controlled reaction zone. Reactor development required extensive design iteration, including plate geometry optimization, melt channeling, temperature-driven flow control, and powder feeding strategies. Following optimization, the system was validated in two multi-hour production runs (13 and 28 hours), yielding a total of 691 g of midazolam with excellent robustness and impurity control. This case illustrates the limitations of hands-off automation in pharmaceutical synthesis. Achieving robust impurity control required real-time monitoring, process understanding, and iterative tuning, hallmarks of a human-in-the-loop approach. For industrial chemists and engineers, the future isn’t about removing the human from the process but designing systems that embed chemical and operational intuition into automation frameworks.
–
Michael Crockett – Cambrex Snapdragon Chemistry
A continuous manufacturing approach to the preparation of GPhos
State of the art ligands like GPhos can be a key cost driver for synthesis when their use is required. This talk will present the development of a two-step continuous process to produce a GPhos that reduces the price of this ligand by 60-80% on kilogram scale. The rapid timelines required for this process were enabled by a plug flow based automated optimization platform. This optimization platform identified suitable conditions for a relatively complex plug flow reaction in less than a day of runtime. Scaling these initial results was relatively straightforward but additional challenges were encountered in the workup and isolation from both organometallic steps. In particular, the quenched magnesium and lithium salts added significant complexity to the continuous extractions employed. Additionally, once longer runtimes were achieved for the cryogenic step, there were clogging issues associated with the transient organolithium species. We were able to minimize this clogging by careful choice of reaction concentration and residence time. These improvements together facilitated scaling to a system that produces 0.6 kg/h of GPhos in 39% overall yield from commercially available materials. To date, this system has been used to produce >50 kg of GPhos and is fit for purpose to produce >100 kg/year should demand rise to that level.
–
David Thompson – Purdue University
Telescoped Synthesis of Lorazepam in Flow
Using a workflow involving route scouting, high-throughput experimentation, and impurity profiling to develop an optimal sequence, we report a novel 5-step route for synthesis of lorazepam in flow. The five steps comprise N-acylation, diazepine ring closure, imine N-oxidation, Polonovski-type rearrangement, and ester hydrolysis to give lorazepam in fewer steps and higher yield than published methods. Each step was optimized with a focus on green solvent selection and replacement of a stoichiometric mCPBA oxidation with catalytic MeReO3 + H2O2/urea before translation to continuous flow. The mean residence times for each of the individual flow reactions summed to a total of 72.5 min (30.8% yield) for the 5-step sequence, compared to a 73.7 hr process (15.2% yield) in batch. We also report a comprehensive analysis of the purity and byproduct profile to maximize the desired product purity in each step utilizing telescoped Chemtrix MR260 reactors in a hybrid flow and batch crystallization process that provides containment of the delorazepam and lorazepam acetate intermediates as well as the lorazepam product.
Acknowledgements: Supported by DARPA HR0011-20-C-0199 and the Purdue Institute for Cancer Research (P30 CA023168).
–
Hannes Gemoets – Halen Technologies
Photochemistry at Scale: Safe Explosion-proof Photoreactor Technologies enabling Pharma Applications
Photochemistry is transforming the chemical manufacturing landscape, offering sustainable, efficient, and scalable solutions. In this presentation, we will explore how the close collaboration between Halen Technologies B.V. and Peschl Ultraviolet GmbH ensures success through their combined expertise, long-standing industry presence, and comprehensive continuous-flow photochemistry solutions. From R&D screening to manufacturing scale, our capabilities span diverse reactor technologies tailored to meet specific application requirements.
We will emphasize the importance of a versatile approach, demonstrating that no single solution fits all. Our portfolio includes both batch and continuous-flow photoreactors such as (continuous) stirred tank reactors, tubular flow photoreactors, static mixer and thin-film flat-bed reactors, side-loop systems, and falling-film photoreactors, each designed to address the different process needs.
A key focus of the presentation is the importance of explosion-proof photoreactor technologies in meeting the rigorous safety requirements of ATEX and NEC 500 certification standards. Scaling photochemistry from R&D to pilot and production levels presents inherent safety risks that demand robust solutions.
Our proprietary high-performance LED technology, designed to achieve both safety and efficiency in hazardous environments, exemplifies how these risks can be effectively mitigated while ensuring reliab
